



SPECIALTY PHARMACEUTICALS ANALYST

GARY NACHMAN

Gary is a senior research analyst in BMO Capital Markets Equity Research covering specialty pharmaceuticals. Prior to joining BMO in February 2016, Gary was most recently a senior research analyst at Goldman Sachs covering specialty pharma. With a sell-side career spanning 16 years covering the specialty pharma industry, Gary was also a senior research analyst at Susquehanna Financial Group and Leerink

Partners, and began his sell-side career at Morgan Stanley. Before getting into equity research, Gary spent a few years in the pharmaceutical industry at Merck where he was a manager of financial evaluations at Merck-Medco. Gary earned his MBA from Columbia University and his undergraduate degree from Binghamton University.

3 Times Square
29th Floor
New York, NY 10036

Tel: (212) 883-5113
Fax: (212) 885-4060
gary.nachman@bmo.com

COVERAGE LIST

Amneal Pharmaceuticals (AMRX-NSDQ)
Amphastar Pharmaceuticals (AMPH-NSDQ)
Aptinyx (APTX-NSDQ)
Aquestive Therapeutics (AQST-NSDQ)
Bausch Health Companies (BHC-NYSE)
Endo International (ENDP-NSDQ)
Flexion Therapeutics (FLXN-NSDQ)
Horizon Therapeutics (HZNP-NSDQ)
Jazz Pharmaceuticals (JAZZ-NSDQ)
Lannett (LCI-NYSE)
Mallinckrodt (MNK-NYSE)
Mylan (MYL-NSDQ)
Neos Therapeutics (NEOS-NSDQ)
Optinose (OPTN-NSDQ)
Pacira BioSciences (PCRX-NSDQ)
SAGE Therapeutics, Inc. (SAGE-NSDQ)
scPharmaceuticals (SCPH-NSDQ)
Sol-Gel Technologies (SLGL-NSDQ)
Teva Pharmaceutical (TEVA-NYSE)
Trevi Therapeutics (TRVI-NSDQ)